Pfizer CEO Albert Bourla addresses a press conference after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021.
John Thys | Pool | Reuters
Pfizer expects to release clinical trial data on how well its Covid-19 vaccine works in 6-month to 5-year old children as early as the end of October, CEO Albert Bourla said Tuesday.
Covid vaccine data for kids between ages 5 to 11 will come much sooner, he said, potentially ready to be submitted to the Food and Drug Administration by the end of this month.
“Then, it is up to the FDA to take their time, and then make a decision,” Bourla said during an interview at Research!America’s 2021 National Health Research Forum.
The CEO’s comments come as many parents say they are anxious to get their children vaccinated, especially as schools reopen and the highly contagious delta variant continues to spread. The strain has led to a surge in hospitalizations across the U.S., including among young kids who are currently ineligible to get the shots.
So far, the Pfizer–BioNTech coronavirus vaccine has been cleared by the FDA for people as young as 12, while Moderna and Johnson & Johnson‘s vaccines have been authorized for adults.
On Friday, FDA officials said they were “working around the clock” to support the approvals of Covid vaccines for kids under age 12.
Dr. Peter Marks, the agency’s top vaccine regulator, said last month the agency would move as “swiftly” as possible on approving the shot for kids under 12 once the companies submit data.
“Currently, there are still trials ongoing and so the agency has to wait for the company to submit the data for those trials,” he said on Aug. 23. “We certainly want to make sure that we get it right.”
